


Feedback repression of PPAR α signaling by *Let-7* microRNA

Graphical abstract



Authors

Tomoki Yagai, Tingting Yan, Yuhong Luo, ..., Moshe Levi, Hozumi Motohashi, Frank J. Gonzalez

Correspondence

gonzalef@mail.nih.gov

In brief

Yagai et al. identify a negative feedback loop involving PPAR α /RXR α control of hepatic lipid metabolism. The study demonstrates *let-7* microRNA repression by PPAR α activation, RNF8 mRNA and protein decay by *let-7* microRNA, and RXR α protein degradation by RNF8 E3 ubiquitin ligase.

Highlights

- PPAR α activation represses *let-7* microRNA expression
- *let-7* microRNA promotes decay of *Rnf8* mRNA and loss of RNF8 protein
- RNF8 promotes RXR α protein degradation
- *let-7*-RNF8-RXR α axis controls hepatic lipid metabolism through a negative feedback loop



Report

Feedback repression of PPAR α signaling by *Let-7* microRNATomoki Yagai,^{1,5,6} Tingting Yan,^{1,5} Yuhong Luo,^{1,5} Shogo Takahashi,^{1,2} Daisuke Aibara,^{1,3} Donghwan Kim,¹ Chad N. Brocker,¹ Moshe Levi,² Hozumi Motohashi,⁴ and Frank J. Gonzalez^{1,7,*}¹Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA²Department of Biochemistry and Molecular and Cellular Biology, Georgetown University, Washington DC, USA³Faculty of Pharmaceutical Science, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan⁴Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan⁵These authors contributed equally⁶Present address: Department of Metabolic Bioregulation, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan⁷Lead contact*Correspondence: gonzalef@mail.nih.gov<https://doi.org/10.1016/j.celrep.2021.109506>

SUMMARY

Peroxisome proliferator-activated receptor α (PPAR α) controls hepatic lipid homeostasis and is the target of lipid-lowering fibrate drugs. PPAR α activation represses expression of *let-7* microRNA (miRNA), but the function of *let-7* in PPAR α signaling and lipid metabolism is unknown. In the current study, a hepatocyte-specific *let-7b/c2* knockout (*let7b/c2*^{ΔHep}) mouse line is generated, and these mice are found to exhibit pronounced resistance to diet-induced obesity and fatty liver. *Let-7* inhibition by hepatocyte-specific *let-7* sponge expression shows similar phenotypes as *let7b/c2*^{ΔHep} mice. RNA sequencing (RNA-seq) analysis reveals that hepatic PPAR α signaling is repressed in *let7b/c2*^{ΔHep} mice. Protein expression of the obligate PPAR α heterodimer partner retinoid X receptor α (RXR α) is reduced in the livers of *let7b/c2*^{ΔHep} mice. Ring finger protein 8 (*Rnf8*), which is a direct target of *let-7*, is elevated in *let7b/c2*^{ΔHep} mouse liver and identified as a E3 ubiquitin ligase for RXR α . This study highlights a *let-7*-RNF8-RXR α regulatory axis that modulates hepatic lipid catabolism.

INTRODUCTION

Let-7 microRNA (miRNA), which is one of the first miRNAs discovered, plays significant roles in embryogenesis, development, metabolism, and oncogenesis (Büssing et al., 2008; Jovanovic and Hengartner, 2006; Schickel et al., 2008; Stefani and Slack, 2008). *Let-7c* belongs to the *let-7* family, with the mature sequence being highly similar among the family members and sharing the same target messenger RNAs (mRNAs). A previous study revealed that mature *let-7c* and its primary transcript, long non-coding RNA (lncRNA) *AK033222* (also known as *Mir99-ahg*), were potently and rapidly repressed by activation of hepatic peroxisome proliferator-activated receptor α (PPAR α), a nuclear receptor that predominantly modulates lipid metabolism (Shah et al., 2007). *Let-7* miRNA potentiates the decay of mRNAs and inhibits protein translation related to cell proliferation, cell differentiation, immune response, and glucose metabolism (Johnson et al., 2005; Liu et al., 2011; Mayr et al., 2007; Schulte et al., 2011; Zhu et al., 2011). Whole-body *let-7* inhibition in transgenic mice expressing *Lin28a* or *Lin28b* results in resistance to hepatic steatosis and obesity (Zhu et al., 2011), and glucose metabolism is also partially improved by a global *let-7* inhibitor (Frost and Olson, 2011), suggesting a role for *let-7* in modulating glycolipid metabolism. However, how hepatic *let-7* modulates lipid metabolism remains unknown.

In this study, PPAR α activation by synthetic Wy-14,643 or endogenous ligands was found to suppress expression of the *let-7* family, an effect dependent on hepatic PPAR α . The biological effects of hepatic *let-7* on hepatic lipid metabolism were further analyzed by use of both hepatocyte-specific *let-7b/c2* knockout (*let7b/c2*^{ΔHep}) mice and hepatocyte-specific *let-7* sponge-mediated *let-7* inhibition. Hepatic *let-7* deficiency prevented hepatic steatosis and obesity induced by high-fat diet (HFD) feeding accompanied by inhibition of the PPAR α signaling. Further analyses revealed that RXR α protein levels were decreased in *let-7*-disrupted hepatocytes. Ring finger protein 8 (*Rnf8*) was identified as a E3 ubiquitin ligase for RXR α , and *Rnf8* mRNA was revealed as a direct target of *let-7*. These data demonstrate that hepatic *let-7* deficiency improves hepatic steatosis during obesity by the RNF8-RXR α axis, suggesting a *let-7*-RNF8-RXR α axis that may act as a negative feedback loop to attenuate PPAR α -mediated lipid-modulating signaling.

RESULTS

Expression of *let-7* miRNA in response to PPAR α activation

The *Let-7* miRNA family consists of 9 mature miRNAs processed from 12 precursors and 8 primary transcripts (Table S1). Although the mature *let-7-5p* sequence is highly similar among



other *let-7* family members, the precursors have unique sequences in their terminal loop and 3p region. To determine the effects of PPAR α activation on individual *let-7* miRNAs, the hepatic levels of the *let-7* miRNA precursors were measured in wild-type (*Ppara*^{+/+}) and hepatocyte-specific *Ppara* knockout (*Ppara* ^{Δ Hep}) mice. Wy-14,643 as a PPAR α -specific agonist was used to induce hepatic PPAR α activation. In response to Wy-14,643 administration, *pre-let-7a-1*, *a-2*, *b*, *c-1*, *c-2*, *e*, *f-1*, *f-2*, *g*, and *miR-98* were significantly decreased, whereas *pre-let-7d* and *pre-let-7i* tended to decrease without significance in wild-type mice but not in *Ppara* ^{Δ Hep} mice (Figure 1A). The total pooled *let-7* precursor abundance was decreased by half after Wy-14643 treatment in livers of *Ppara*^{+/+} mice but not *Ppara* ^{Δ Hep} mice (Figure 1B). To analyze the effect of PPAR α activation by endogenous ligands, mice were fasted for 24 h, which leads to increased PPAR α signaling resulting from increased endogenous metabolites that are PPAR α agonists (Kersten et al., 1999). Hepatic *pre-let-7a-1*, *b*, *d*, *f-1*, and *f-2* were significantly decreased in fasted wild-type mice but not in *Ppara* ^{Δ Hep} mice (Figure 1C), a phenotype not observed in fed mice. The total pooled *let-7* precursor abundance was decreased by approximately 40% after fasting (Figure 1D). These data demonstrate that PPAR α activation by either a chemical agonist or endogenous fatty acid induces a decrease of *let-7* expression in a hepatocyte PPAR α -dependent manner.

A time course analysis of hepatic mature *let-7* expression after PPAR α activation further revealed that mature *let-7* family's transcripts started to decrease by 12 h after Wy-14,643 administration. All *let-7* family members were significantly repressed within 24 h (Figure 1E). Previous studies revealed that RNA-binding proteins *Lin28a* and *Lin28b* were highly expressed during embryogenesis and upregulated in some cancers to selectively block the maturation of *let-7*. *Lin28* selectively binds the terminal loop region of *let-7* precursors and inhibits miRNA processing (Piskounova et al., 2008). To explore whether *Lin28* plays a role in the regulation of *let-7* during PPAR α activation, hepatic *Lin28a* and *Lin28b* were quantified in response to Wy-14643 treatment. However, *Lin28a* was not changed by Wy-14643 treatment, with *Lin28b* undetectable in the liver (Figures S1A and S1B).

Hepatocyte-specific *let-7b/c2* knockout results in resistance to obesity

To further analyze the physiological roles of hepatic *let-7*, hepatocyte-specific *let-7b/c2* knockout (*let7b/c2* ^{Δ Hep}) mice were generated by mating *Alb-Cre* (Yakar et al., 1999) and *let-7b/c2 floxed* (Madison et al., 2013) mouse lines. *Let7b/c2* ^{Δ Hep} mice showed normal development and fertility, with hepatic *let-7b* and *c2* levels decreased by more than 80% (Figures S1C and S1D). Interestingly, *let7b/c2* ^{Δ Hep} mice showed significantly less weight gain under HFD challenge than similarly treated *let7b/c2*^{+/+} mice (Figures 2A and 2B), without changes in food intake (Figure S1E). Hematoxylin and eosin (H&E) staining and oil red O (ORO) staining revealed less lipid accumulation in the livers of HFD-fed *let7b/c2* ^{Δ Hep} mice than that in similarly treated wild-type mice (Figure 2C). After 8 weeks of HFD feeding, the lean-to-body weight ratio was significantly increased in *let7b/c2* ^{Δ Hep} mice (Figure 2D), whereas both fat-body weight ratios

and liver-body weight ratios were significantly lower (Figures 2E and 2F). Serum triglyceride (TG) and total cholesterol (TC) were also markedly decreased in *let7b/c2* ^{Δ Hep} mice (Figures 2G and S1F). These data indicated that *let7b/c2* ^{Δ Hep} mice are resistant to HFD-induced obesity.

In addition, serum alanine aminotransferase (ALT) was decreased in *let7b/c2* ^{Δ Hep} mice, suggesting less hepatotoxicity from HFD feeding (Figure S1G). Although both hepatic TG and TC were significantly decreased (Figures S1H and S1I), non-esterified fatty acids (NEFAs) were increased in *let7b/c2* ^{Δ Hep} mice (Figure S1J). These data suggested that *let7b/c2* ^{Δ Hep} mice had lower constitutive hepatic fatty acid esterification and/or lipid synthesis, whereas fatty acid intake was not changed by the loss of hepatic *let-7b/c2*. In normal chow-diet-fed mice, no significant differences were found in body weight, serum TG, or hepatic TC and TG (Figures S2A, S2B, S2D, and S2E) between the two genotypes, whereas serum TC was slightly decreased in *let7b/c2* ^{Δ Hep} mice (Figures S2C). Previous studies showed that whole-body *let-7* miRNA inhibition modulated glucose metabolism (Frost and Olson, 2011; Zhu et al., 2011). To determine whether these phenotypes were derived from glucose metabolism, insulin, glucose, and pyruvate tolerance tests (ITT, GTT, and PTT, respectively) were performed and no significant differences were found between *let7b/c2*^{+/+} and *let7b/c2* ^{Δ Hep} mice (Figures S2F, S2G, and S2H). These data suggest that hepatic *let7b/c2* disruption improves fatty liver and attenuates obesity during HFD feeding, whereas hepatocyte *let7b/c2* disruption does not affect insulin sensitivity.

Hepatocyte-specific *Let-7* sponge expression results in resistance to obesity

miRNA sponges are a well-recognized method to perform loss-of-function analyses of miRNAs *in vivo* and *in vitro* (Ebert and Sharp, 2010). Sponge RNA has complementary binding sites for a given miRNA and is degraded instead of the target mRNAs as a decoy, repressing miRNA activity. To further analyze the role of hepatic *let-7* in obesity and hepatic steatosis, an adeno-associated virus 8 (AAV8) designated for hepatocyte-specific expression of *let-7* sponge was constructed (*let-7* sponge) (Figures S3A and S3B). Primary hepatocytes were transduced with AAV-EGFP, and 5 days after infection, a pronounced EGFP expression was observed, indicating successful infection of cells by AAV. Conversely, *let-7* sponge AAV-infected hepatocytes exhibited very low EGFP fluorescence, suggesting that *let-7* miRNA was abundantly expressed in hepatocytes (Figure 2H). EGFP DNA quantification confirmed that the infection efficiency of *let-7* sponge expressing AAV was equivalent with AAV-EGFP control (Figure S3C). To inhibit *let-7* activity *in vivo*, the recombinant AAV vectors were intravenously injected to wild-type mice followed by HFD feeding for 8 weeks. *Let-7* sponge AAV-injected mice showed less body weight gains starting from 3 weeks after HFD feeding than the EGFP AAV group (Figure 2I). Lipid accumulation was decreased in *let-7* sponge AAV-treated liver (Figure S3D). The *let-7* sponge group did not show significant differences in lean body weight ratio and liver-body weight ratio (Figures 2J and 2L), whereas the fat-weight-to-body-weight ratio was decreased (Figure 2K). Serum and hepatic TG were also significantly decreased (Figures 2M and S3F), whereas serum




Figure 1. Expression of *let-7* miRNA family members is decreased in mouse liver in response to $PPAR\alpha$ activation

(A–D) Fold change of *let-7* miRNA precursors in $PPAR\alpha$ -activated $Ppara^{+/+}$ and $Ppara^{\Delta Hep}$ mouse livers measured by qRT-PCR. Individual *let-7* miRNA precursor expression in livers treated with Wy-14,643 (A) or overnight fasting (C). Precursor abundance ratios in mice treated with Wy-14,643 (B) or overnight fasting (D). Data are normalized to *Actb* expression and presented as mean \pm SEM (n = 4 mice per group; *p < 0.05, #p < 0.01, §p < 0.001)

(E) Time course of mature *let-7* miRNA abundance in wild-type mouse liver after Wy-14,643 administration measured by qRT-PCR. Data are normalized to *U6* expression and presented as mean \pm SEM (n = 4 mice per group; *p < 0.05, **p < 0.01, ***p < 0.001)

TC, hepatic TC, and NEFA did not show significant alterations (Figures S3E, S3G, and S3H). ITT and GTT did not show significant differences (Figures S3I and S3J). Consistent with the phenotype observed in $let7b/c2^{\Delta Hep}$ mice, these data indicated that inhibition of mature *let-7* activity resulted in lipid synthesis reduction and obesity resistance.


$PPAR\alpha$ target gene mRNAs are lower in $let7b/c2^{\Delta Hep}$ livers

To identify potential mechanisms contributing to the observed phenotypes mediated by hepatic *let-7* deletion, RNA sequencing (RNA-seq) was carried out to analyze the gene expression profiles in livers of $let-7b/c2^{+/+}$ and $let-7b/c2^{\Delta Hep}$ mice fed a HFD. Pathway analysis revealed that $PPAR\alpha$, β/δ , γ , and farnesoid X receptor (FXR) pathways were robustly inhibited in the $let7b/c2^{\Delta Hep}$ livers (Figures 3A and S1K; Table S2). These are all ligand-activated nuclear receptors that heterodimerize with RXR α . mRNA-encoding proteins involved in fatty acid oxidation,

cell proliferation (Figure 3B), lipid accumulation, and glucose metabolism (Figure 3C) were all found to be decreased by hepatic *let-7* depletion. Western blot analysis revealed a significant decrease in expression of $PPAR\alpha$ target gene protein products, including cytochrome P450 ω -hydroxylase 4A (CYP4A); enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase (EH-HADH); hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase, α subunit (HADHA); and keratin, type I cytoskeletal 23 (KRT23) in $let7b/c2^{\Delta Hep}$ livers (Figure 3D). Several $PPAR\alpha$ target genes were repressed even in 1-week HFD-fed livers when the body weight was not altered between $let7b/c2^{+/+}$ and $let7b/c2^{\Delta Hep}$ mice (Figure S2I), indicating the inhibition of $PPAR$ signaling was independent of body weight change.

RXR α protein is reduced by *Let-7* miRNA inhibition

Nuclear receptors, including the $PPAR$ family and FXR, form obligate heterodimers with RXR α and modulate transcription by



binding to their respective responsive elements in the enhancer/promoter regions of target genes (Rigano et al., 2017). Given that PPAR α , β/δ , γ , and FXR pathways were significantly repressed, it is reasonable to speculate whether their common heterodimer RXR is regulated by *let-7*. No significant differences in *Rxra* or *Ppara* mRNA levels were found between *let7b/c2^{+/+}* and *let7b/c2^{ΔHep}* livers (Figures S4A and S4B), whereas the RXR α protein in *let-7b/c2^{ΔHep}* livers was significantly decreased compared with *let7b/c2^{+/+}* livers (Figure 3F). Then, freshly isolated *let7b/c2^{+/+}* and *let7b/c2^{ΔHep}* primary hepatocytes were subjected to RNA and protein analyses, revealing that the RXR α protein but

not the *Rxra* mRNA was decreased in *let7b/c2^{ΔHep}* hepatocytes (Figures 3E and S4C). Consistently, forced expression of *let-7* sponge resulted in a decrease in the RXR α protein but not *Rxra* mRNA (Figures 3G and S4D). In contrast, *let-7c-1* overexpression by AAV led to a significant increase of the RXR α protein but not *Rxra* mRNA (Figures 3H and S4D). A previous study revealed that RXR α inhibition resulted in obesity and amelioration of hepatic steatosis (Yamauchi et al., 2001). An RXR α inhibition experiment was performed in primary hepatocytes by use of the RXR α inhibitor HX-531. Lipid accumulation induced by palmitic acid treatment was repressed by HX-531 administration




Figure 3. PPAR α target gene expressions were repressed by RXR α protein reduction in *let7b/c2 Δ Hep* and *let-7* sponge AAV-transduced mice (A) Heatmap of PPAR α target genes identified by differential gene expression analysis of RNA-seq data from *let7b/c2 $^{+/+}$* and *let7b/c2 Δ Hep* livers after HFD feeding. (B and C) mRNA analysis by qRT-PCR of PPAR α target genes involved in fatty acid oxidation and cell proliferation (B) and lipid accumulation and glucose metabolism (C) in HFD-fed *let7b/c2 $^{+/+}$* and *let7b/c2 Δ Hep* livers. (D) Western blot analysis for PPAR α target genes in HFD-fed *let7b/c2 $^{+/+}$* and *let7b/c2 Δ Hep* liver lysates. (E) Western blot analysis of PPAR α and RXR α protein expression in nuclear fractions isolated from *let7b/c2 $^{+/+}$* and *let7b/c2 Δ Hep* hepatocytes. (F–H) Western blot analysis of RXR α and the densitometric quantification in whole-liver lysates from *let7b/c2 Δ Hep* mice (F), *let-7* sponge expressing AAV-infected mice (G), and *pre-let-7c-1*-AAV-infected mice (H). Data are presented as mean \pm SEM (n = 4–5 mice per group; *p < 0.05, **p < 0.01, ***p < 0.001)

in hepatocytes (Figure S4E). Western blot analysis of RXR α in the livers of mice fed on chow or HFD and treated with vehicle or Wy-14643 demonstrated that PPAR α activation resulted in lower RXR α protein levels under both chow diet and HFD (Figure S4F). These results indicate that *let-7* positively modulates the RXR α protein but not *Rxra* mRNA levels, which may contribute to less hepatic lipid accumulation in livers of *let-7*-deficient mice.

Rnf8 mRNA is a *let-7* miRNA direct target

The ubiquitin-proteasome system is a multi-step process that regulates protein stability and involves enzymes of three different classes. Ubiquitin is activated by the E1 enzyme, and then the E2 enzyme transfers ubiquitin to lysine residues in the target protein. The E3 enzyme binds with the target protein and mediates ubiquitination.

The polyubiquitinated proteins are then degraded by the 26S proteasome (Glickman and Ciechanover, 2002). Recent studies demonstrated that *Rnf8* encoded an E3 ubiquitin ligase targeting various proteins (Fritsch et al., 2014; Lee et al., 2016; Paul and Wang, 2017). Previous research revealed that RNF8 bound to RXR α in the nucleus (Takano et al., 2004). Because *let7b/c2 Δ Hep* mice exhibited a decrease in the RXR α protein but not *Rxra* mRNA, the question arises whether the RXR α protein is degraded by the ubiquitin-proteasome system. To determine whether *Rnf8* is a direct target of *let-7* miRNA, the sequence of *Rnf8* was subjected to bioinformatic analysis using open-source algorithms including miRWalk, TargetScan, and microRNA.org. These analyses identified two potential *let-7* miRNA binding sites; site 1 is located within the coding

sequence, and site 2 is in the 3' UTR (Figure 4A). Western blot analyses for the RNF8 protein were performed with an antibody verified with *Rnf8*-overexpressed cell lysates (Figure S4J). Western blot and qRT-PCR analyses revealed that the RNF8 protein and *Rnf8* mRNA were significantly increased in *let7b/c2*^{ΔHep} livers respectively (Figures 4B and 4C). The protein and mRNA abundance in mice infected with *let-7* sponge-expressed AAV were also significantly elevated (Figures 4D and 4E). In contrast, *pre-let-7c-1*-expressing mouse livers showed a significant decrease of the RNF8 protein (Figure 4F). The *Rnf8* mRNA showed a similar tendency without statistical significance (Figure S4G), suggesting that translational inhibition by *let-7* miRNA contributed to the RNF8 protein decrease more than mRNA decay. To assess whether *Rnf8* mRNA is a direct target of *let-7* miRNA, 3' UTR reporter assays were performed. The wild-type *Rnf8* 3' UTR including a predicted *let-7* binding site was cloned into a luciferase reporter vector, and a mutant vector lacking a *let-7* binding site candidate was also constructed. Using wild-type *Rnf8* 3' UTR, luciferase activity was significantly decreased by co-transfection with a *let-7c* mimic in HepG2 cells. Conversely, luciferase activity was unchanged with the mutated vector (Figure 4G). These data indicated that *Rnf8* mRNA was a direct target of *let-7* miRNA.

RNF8 is a E3 ubiquitin ligase for the RXR α protein

To analyze whether RNF8 is involved in RXR α ubiquitination in hepatic cells, RNF8 and RXR α expression vectors were co-transfected into Hepa-1c1c7 (Hepa-1) cells. The cell lysates were subjected to western blot analysis, revealing that the RXR α protein was significantly decreased when RNF8 was co-transfected (Figures 4H and 4I). *Rnf8* mRNA was increased by more than 4,000-fold compared with the control expression vector-transfected group (Figure 4J). Co-transfection with *Rnf8* had no impact on increases in *Rxra* mRNA (Figure 4K). These results suggested that RNF8 expression did not affect *Rxra* mRNA levels but decreased RXR α protein levels *in vitro*.

To determine whether the decrease of the RXR α protein was caused by the ubiquitin-proteasome pathway, Hepa-1 cells transfected with RNF8 and RXR α expression vectors were treated with the proteasome inhibitor MG-132. The MG-132-treated group showed a 1.4-fold increase of the RXR α protein, whereas only a small increase was noted without RNF8 (Figures 4L and S4H). Given that RNF8 is a E3 ubiquitin ligase for RXR α , the RXR α protein should be polyubiquitinated in Hepa-1 cells. Hepa-1 cells transfected with an RXR α expression vector together with or without an RNF8 expression vector were subjected to co-immunoprecipitation (coIP) assays to detect polyubiquitinated RXR α . Western blot analysis of the immunoprecipitated samples revealed that cells transfected with RXR α and RNF8 expression vectors contained significantly more polyubiquitinated RXR α than the non-RNF8 expressing cells (Figure 4M). K48 polyubiquitin is a polyubiquitin chain contributing to protein degradation in the ubiquitin/proteasome pathway. Western blot analysis for RNF8- and RXR α -overexpressed cell lysate was performed with a K48 polyubiquitin-specific antibody, revealing that RNF8 accelerated K48 polyubiquitination of RXR α (Figure S4I). Together with data in the current study, a 3-step inhibition mechanism

for the PPAR α /RXR α pathway in fatty liver was elucidated (Figure 4N)

DISCUSSION

Although whole-body *let-7* inhibition in transgenic mice expressing *Lin28a* or *Lin28b* improves hepatic steatosis and obesity (Zhu et al., 2011), and a global *let-7* inhibitor partially improves glucose metabolism (Frost and Olson, 2011), the role of *let-7* in hepatic lipid metabolism has previously not been explored. In the current study, for the first time, a pronounced resistance to HFD-induced obesity was noted in mice lacking hepatic *let-7* or in mice infected with AAV expressing a *let-7* miRNA sponge. However, *let-7* did not influence insulin sensitivity or glucose tolerance. Mechanistically, a *let-7*-RNF8-RXR α axis was identified to explain the observed phenotypes in the current study. These results provide novel insights into *let-7* miRNA modulation of metabolic diseases.

A striking finding of this study is that the *let-7*-RNF8-RXR α axis modulates lipid homeostasis during obesity. When hepatic *let-7b/c2* was genetically disrupted or inhibited by *let-7* sponge, the mice showed resistance to HFD-induced fatty liver and obesity. RNA-seq data revealed a consistent downregulation of the target genes of several nuclear receptors, including PPAR α , that all shared RXR α as the heterodimer partner, leading to the hypothesis that RXR α is modulated by *let-7* deficiency. Hepatic RXR α protein, but not mRNA, was decreased in the liver of hepatic *let-7*-deficient mice as well as in primary hepatocytes isolated from hepatic *let-7*-deficient mice, possibly contributing to repression of nuclear receptor pathways including PPAR α signaling. The positive regulation of *let-7* in RXR α protein expression was further supported by the gain-of-function data from overexpressing *let-7* in both livers and cultured hepatocytes. Given that the RXR α protein, but not mRNA, levels were modulated by *let-7*, a posttranslational modulation of RXR α by *let-7* was suspected. Although RNF8 is known to bind with RXR α in the nucleus (Takano et al., 2004), we found that RNF8 acted as an E3 ubiquitin ligase for RXR α protein *in vitro* and regulated protein degradation of RXR α at the posttranslational level. To explain how RNF8 was increased in hepatic *let-7*-deficient livers, RNF8 protein levels were first found to be decreased in the hepatic *let-7*-deficient livers and increased in hepatic *let-7*-overexpressing livers, and then *Rnf8* mRNA was further identified as a mRNA target of *let-7*. These data together support the existence of a *let-7*-RNF8-RXR α axis in the liver.

Implicit in the present findings is that decreased RXR α expression may contribute to the phenotype of hepatic *let-7*-deficient mice. Although RXR α inhibition is already known to ameliorate obesity and hepatic steatosis in mice *in vivo* (Yamauchi et al., 2001), we further demonstrated that RXR α inhibition markedly inhibited lipid accumulation in mouse primary hepatocytes in the current study, which together support the view that RXR α inhibition contributes to the improvement of hepatic steatosis and obesity. RXR α is a versatile nuclear receptor contributing to several cellular processes ranging from cell proliferation to lipid metabolism by modulating different target genes (Evans and Mangelsdorf, 2014; Lefebvre et al., 2010). Activation of different RXR-partnered nuclear receptors yields different, or even




Figure 4. RNF8 is decayed by *let-7* miRNA, and RXRα protein is ubiquitinated by RNF8 E3 ubiquitin ligase

(A) Predicted *let-7* miRNA binding sites in *Rnf8* mRNA. (B–F) Western blot analysis and densitometric quantification of RNF8 protein (B, D, and F) and qRT-PCR of *Rnf8* mRNA (C and E) in *let7b/c2^{+/+}* and *let7b/c2^{ΔHep}* (B and C); EGFP and *let-7* sponge AAV-transduced (D and E); EGFP and *pre-let-7c-1* AAV-transduced (F) livers treated with HFD feeding. (G) 3' UTR reporter assays in HepG2 cells transfected with *Rnf8* wild-type or mutant 3' UTR reporter constructs and a *let-7c* mimic expression vector. (H and I) Western blot analysis (H) and densitometric quantification (I) of RXRα expression in *Rxra*- and *Rnf8*-transfected Hepa-1 cells. (J and K) Fold change of *Rnf8* (J) and *Rxra* (K) mRNA by qRT-PCR analysis in *Rxra*- and *Rnf8*-transfected Hepa-1 cells. (L) Western blot analysis and the densitometric quantification of RXRα in *Rxra*- and *Rnf8*-transfected Hepa-1 cells treated with the proteasome inhibitor MG-132. (M) Ubiquitination assays for *Rxra*- and *Rnf8*-transfected and MG-132-treated Hepa-1 cells. RXRα was immunoprecipitated and polyubiquitin detected by anti-ubiquitin antibody. RXRα expression was confirmed in whole-cell lysate as input. (N) Scheme of 3-step inhibition for PPARα/RXRα pathway that the current study demonstrates.

opposite, effects in modulating the obesity-associated metabolic diseases (Cariou et al., 2006; Gao et al., 2009; Ma et al., 2013; Spruiell et al., 2014). Because hepatic *let-7* deficiency alleviated fatty liver and obesity in HFD-fed mice, the beneficial effects of RXRα inhibition might be superior to its harmful effects in restricting hepatic lipid accumulation. In this case, the decreased RXRα expression in hepatic *let-7*-deficient mice may contribute to the resistance to HFD-induced obesity and fatty liver. Although decreased RXRα expression by hepatic *let-7* deficiency is suggested to contribute to the phenotype, we cannot rule out the possibility that hepatic *let-7* deficiency improved obesity and fatty liver by other mechanisms.

A PPARα-*let-7*-RNF8-RXRα negative feedback loop is suggested as one potential downstream pathway after PPARα activation. In the current study, hepatocyte-specific *Ppara* knockout mice in combination with both chemical PPARα agonist and fasting-induced increase of endogenous PPARα ligands were used and confirmed a hepatocyte PPARα-dependent modulation of hepatic *let-7* expression. Once hepatocyte PPARα was activated, expression of the hepatic *let-7* family was inhibited, and the hepatic PPARα signaling pathway was reduced by the proposed *let-7*-RNF8-RXRα axis once hepatic *let-7* was inhibited, as revealed by using hepatic *let-7*-deficient mice. These results suggest a possible PPARα-*let-7*-RNF8-RXRα negative feedback

loop, with the detailed mechanisms underlying PPAR α -activation-repressed *let-7* expression still awaiting further study.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
 - Lead contact
 - Materials availability
 - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Animals
- **METHOD DETAILS**
 - Quantitative RT-PCR
 - Hematoxylin and eosin and oil red O staining
 - Biochemical analyses for triglyceride, total cholesterol, and non-esterified fatty acid
 - Biochemical analysis for serum alanine aminotransferase
 - Insulin, Glucose, and Pyruvate tolerance test
 - Construction of hepatocyte-specific *let-7* sponge and pre-*let-7c-1* expression adeno-associated virus (AAV) vector
 - Primary hepatocyte isolation and culture
 - RNA-seq and pathway analysis
 - Ubiquitination assay for RXR α protein
 - Western blot analysis
 - Dual luciferase reporter assay
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2021.109506>.

ACKNOWLEDGMENTS

We thank Linda G. Byrd for assistance with the mouse studies and Oksana Gavrilova for mouse body composition analysis. This work was funded by the National Cancer Institute Intramural Research Program. T. Yagai and S. Takahashi were supported in part by a fellowship from the Japan Society for the Promotion of Science. The funding sponsors had no role in the design, collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.

AUTHOR CONTRIBUTIONS

T. Yagai, T. Yan, Y.L., S.T., D.A., D.K., and C.N.B. performed the research and analyzed the data. T. Yagai, T. Yan, M.L., H.M., and F.J.G. designed and supervised the research and wrote the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 20, 2019

Revised: March 12, 2021

Accepted: July 20, 2021

Published: August 10, 2021

REFERENCES

- Brocker, C.N., Yue, J., Kim, D., Qu, A., Bonzo, J.A., and Gonzalez, F.J. (2017). Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells. *Am. J. Physiol. Gastrointest. Liver Physiol.* *312*, G283–G299.
- Büssing, I., Slack, F.J., and Grosshans, H. (2008). *let-7* microRNAs in development, stem cells and cancer. *Trends Mol. Med.* *14*, 400–409.
- Cariou, B., van Harmelen, K., Duran-Sandoval, D., van Dijk, T.H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J.-C., Gonzalez, F.J., et al. (2006). The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. *J. Biol. Chem.* *281*, 11039–11049.
- Ebert, M.S., and Sharp, P.A. (2010). MicroRNA sponges: progress and possibilities. *RNA* *16*, 2043–2050.
- Evans, R.M., and Mangelsdorf, D.J. (2014). Nuclear Receptors, RXR, and the Big Bang. *Cell* *157*, 255–266.
- Fritsch, J., Stephan, M., Tchikov, V., Winoto-Morbach, S., Gubkina, S., Kabelitz, D., and Schütze, S. (2014). Cell fate decisions regulated by K63 ubiquitination of tumor necrosis factor receptor 1. *Mol. Cell. Biol.* *34*, 3214–3228.
- Frost, R.J., and Olson, E.N. (2011). Control of glucose homeostasis and insulin sensitivity by the *Let-7* family of microRNAs. *Proc. Natl. Acad. Sci. USA* *108*, 21075–21080.
- Gao, J., He, J., Zhai, Y., Wada, T., and Xie, W. (2009). The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. *J. Biol. Chem.* *284*, 25984–25992.
- Glickman, M.H., and Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. *Physiol. Rev.* *82*, 373–428.
- Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K.L., Brown, D., and Slack, F.J. (2005). RAS is regulated by the *let-7* microRNA family. *Cell* *120*, 635–647.
- Jovanovic, M., and Hengartner, M.O. (2006). miRNAs and apoptosis: RNAs to die for. *Oncogene* *25*, 6176–6187.
- Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B., and Wahli, W. (1999). Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. *J. Clin. Invest.* *103*, 1489–1498.
- Kim, D., Brocker, C.N., Takahashi, S., Yagai, T., Kim, T., Xie, G., Wang, H., Qu, A., and Gonzalez, F.J. (2019). Keratin 23 is a peroxisome proliferator-activated receptor α -dependent, MYC-amplified oncogene that promotes hepatocyte proliferation. *Hepatology* *70*, 154–167.
- Lee, H.J., Li, C.F., Ruan, D., Powers, S., Thompson, P.A., Frohman, M.A., and Chan, C.H. (2016). The DNA damage transducer RNF8 facilitates cancer chemoresistance and progression through Twist activation. *Mol. Cell* *63*, 1021–1033.
- Lefebvre, P., Benomar, Y., and Staels, B. (2010). Retinoid X receptors: common heterodimerization partners with distinct functions. *Trends Endocrinol. Metab.* *21*, 676–683.
- Leid, M., Kastner, P., Lyons, R., Nakshatri, H., Saunders, M., Zacharewski, T., Chen, J.-Y., Staub, A., Garnier, J.-M., Mader, S., et al. (1992). Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. *Cell* *68*, 377–395.
- Li, G., Xie, C., Lu, S., Nichols, R.G., Tian, Y., Li, L., Patel, D., Ma, Y., Brocker, C.N., Yan, T., et al. (2017). Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. *Cell Metab.* *26*, 672–685.e4.
- Liu, Y., Chen, Q., Song, Y., Lai, L., Wang, J., Yu, H., Cao, X., and Wang, Q. (2011). MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. *FEBS Lett.* *585*, 1963–1968.
- Ma, Y., Huang, Y., Yan, L., Gao, M., and Liu, D. (2013). Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. *Pharm. Res.* *30*, 1447–1457.

- Madison, B.B., Liu, Q., Zhong, X., Hahn, C.M., Lin, N., Emmett, M.J., Stanger, B.Z., Lee, J.S., and Rustgi, A.K. (2013). LIN28B promotes growth and tumorigenesis of the intestinal epithelium via Let-7. *Genes Dev.* 27, 2233–2245.
- Mayr, C., Hemann, M.T., and Bartel, D.P. (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. *Science* 315, 1576–1579.
- Park, T.K., Wu, Z., Kjellstrom, S., Zeng, Y., Bush, R.A., Sieving, P.A., and Colosi, P. (2009). Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. *Gene Ther.* 16, 916–926.
- Paul, A., and Wang, B. (2017). RNF8- and Ube2S-dependent ubiquitin lysine 11-linkage modification in response to DNA damage. *Mol. Cell* 66, 458–472.e5.
- Piskounova, E., Viswanathan, S.R., Janas, M., LaPierre, R.J., Daley, G.Q., Sliz, P., and Gregory, R.I. (2008). Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. *J. Biol. Chem.* 283, 21310–21314.
- Rigano, D., Sirignano, C., and Tagliatela-Scafati, O. (2017). The potential of natural products for targeting PPAR α . *Acta Pharm. Sin. B* 7, 427–438.
- Schickel, R., Boyerinas, B., Park, S.M., and Peter, M.E. (2008). MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. *Oncogene* 27, 5959–5974.
- Schmittgen, T.D., Lee, E.J., Jiang, J., Sarkar, A., Yang, L., Elton, T.S., and Chen, C. (2008). Real-time PCR quantification of precursor and mature microRNA. *Methods* 44, 31–38.
- Schulte, L.N., Eulalio, A., Mollenkopf, H.J., Reinhardt, R., and Vogel, J. (2011). Analysis of the host microRNA response to Salmonella uncovers the control of major cytokines by the let-7 family. *EMBO J.* 30, 1977–1989.
- Shah, Y.M., Morimura, K., Yang, Q., Tanabe, T., Takagi, M., and Gonzalez, F.J. (2007). Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. *Mol. Cell. Biol.* 27, 4238–4247.
- Spruiell, K., Richardson, R.M., Cullen, J.M., Awumey, E.M., Gonzalez, F.J., and Gyamfi, M.A. (2014). Role of pregnane X receptor in obesity and glucose homeostasis in male mice. *J. Biol. Chem.* 289, 3244–3261.
- Stefani, G., and Slack, F.J. (2008). Small non-coding RNAs in animal development. *Nat. Rev. Mol. Cell Biol.* 9, 219–230.
- Takano, Y., Adachi, S., Okuno, M., Muto, Y., Yoshioka, T., Matsushima-Nishiwaki, R., Tsurumi, H., Ito, K., Friedman, S.L., Moriwaki, H., et al. (2004). The RING finger protein, RNF8, interacts with retinoid X receptor α and enhances its transcription-stimulating activity. *J. Biol. Chem.* 279, 18926–18934.
- Yagai, T., Miyajima, A., and Tanaka, M. (2014). Semaphorin 3E secreted by damaged hepatocytes regulates the sinusoidal regeneration and liver fibrosis during liver regeneration. *Am. J. Pathol.* 184, 2250–2259.
- Yakar, S., Liu, J.L., Stannard, B., Butler, A., Accili, D., Sauer, B., and LeRoith, D. (1999). Normal growth and development in the absence of hepatic insulin-like growth factor I. *Proc. Natl. Acad. Sci. USA* 96, 7324–7329.
- Yamauchi, T., Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota, N., Terauchi, Y., Tsuchida, A., et al. (2001). Inhibition of RXR and PPAR γ ameliorates diet-induced obesity and type 2 diabetes. *J. Clin. Invest.* 108, 1001–1013.
- Zhu, H., Shyh-Chang, N., Segrè, A.V., Shinoda, G., Shah, S.P., Einhorn, W.S., Takeuchi, A., Engreitz, J.M., Hagan, J.P., Kharas, M.G., et al.; DIAGRAM Consortium; MAGIC Investigators (2011). The Lin28/let-7 axis regulates glucose metabolism. *Cell* 147, 81–94.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal anti-CYP4A	Santa Cruz	Cat# sc-271983; RRID: AB_10715105
Mouse monoclonal anti-RNF8	Santa Cruz	Cat# sc-271462; RRID: AB_10648902
Mouse monoclonal anti-Ub	Santa Cruz	Cat# sc-8017; RRID: AB_628423
Mouse monoclonal HA-probe	Santa Cruz	Cat# sc-7392; RRID: AB_627809
Mouse monoclonal β -Actin	Santa Cruz	Cat# sc-47778; RRID: AB_626632
Rabbit polyclonal anti-EHHADH	Proteintec	Cat# 26570-1-AP; RRID: AB_2880556
Rabbit polyclonal anti-HADHA	Proteintec	Cat# 10758-1-AP; RRID: AB_2115593
Rabbit polyclonal anti-KRT23	Origene	Cat# TA321839
Rabbit monoclonal anti-RXR α	Abcam	Cat# ab125001; RRID: AB_10975632
Rabbit polyclonal anti-Histon H3	Abcam	Cat# ab1791; RRID: AB_302613
Rabbit polyclonal anti-PPAR α	Abcam	Cat# ab126285
Rabbit monoclonal anti-K48-linkage Ubiquitin	Cell Signaling Technology	Cat# 8081; RRID: AB_10859893
Bacterial and virus strains		
AAV8-Alb-EGFP; -let-7 sponge; -pre-let-7c-1	This paper	N/A
Chemicals, peptides, and recombinant proteins		
Protease inhibitor cocktail	Sigma-Aldrich	Cat# P9599
Protein A Agarose	Sigma-Aldrich	Cat# P2545
Wy-14,643	APEX BIO	Cat# A4305
MG-132	Sigma-Aldrich	Cat# M8699
Dexamethasone	Sigma-Aldrich	Cat# D2915
Insulin-Transferrin-Selenium	Sigma-Aldrich	Cat# I3146
Glutamax Supplement	Thermo Fisher Scientific	Cat# 35050079
HEPES	Thermo Fisher Scientific	Cat# 15630080
Humulin R (human recombinant insulin)	Eli Lilly	N/A
Critical commercial assays		
Taqman microRNA Assay	Thermo Fisher Scientific	Cat# 4427975 Assay ID:000377; 000378; 000379; 002283; 002406; 000382; 002282; 002221; 000577
L-Type Triglyceride M	Fujifilm Wako Diagnostics	Cat# 994-02891; 990-02991
Cholesterol E	Fujifilm Wako Diagnostics	Cat# 999-02601
HR Series NEFA-HR(2)	Fujifilm Wako Diagnostics	Cat# 999-34691; 995-34791; 991-34891; 993-35191; 276-76491
SimpleChIP Plus Enzymatic Chromatin IP kit	Cell Signaling Technology	Cat# 9005
ALT assay kit	Catachem Inc	Cat# V165-12
Deposited data		
Raw and analyzed data	This paper	GEO: GSE165521
Experimental models: Cell lines		
Human: Hep G2 cells	ATCC	Cat# HB-8065
Mouse: Hepa-1c1c7 cells	ATCC	Cat# CRL-2026

(Continued on next page)

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Continued		
Experimental models: Organisms/strains		
Mouse: C57BL/6	Charles River Laboratories	Strain Code: 027
Mouse: <i>Ppara</i> wild-type (<i>Ppara</i> ^{+/+})	Brocker et al., 2017	N/A
Mouse: Hepatocyte-specific <i>Ppara</i> knockout (<i>Ppara</i> ^{ΔHep})	Brocker et al., 2017	N/A
Mouse: <i>Alb-Cre</i>	Yakar et al., 1999	N/A
Mouse: <i>let7b/c2</i> flox	Madison et al., 2013	N/A
Oligonucleotides		
miRIDIAN microRNA Mimic Negative Control #1	Dharmacon	Cat# CN-001000-01-05
miRIDIAN microRNA hsa-let-7c-5p mimic	Dharmacon	Cat# C-300477-03-0005
let-7 sponge; see Figure S4	Integrated DNA Technologies	N/A
Primers for qPCR; see Table S1	This paper	N/A
Recombinant DNA		
pscAAV-ALBp-EGFP	Kim et al., 2019	N/A
pSR449B, pAAV8RC	Park et al., 2009	N/A
pCMV-MIR-MirLet7c-1	Origene	Cat# SC400710
pSG5-mouse <i>Rxra</i>	Leid et al., 1992	N/A
pCMV6-mouse <i>Rnf8</i>	Origene	Cat# MR207821
pRK5-HA-Ubiquitin-WT	Addgene	Cat# 17608
pGL4.27	Promega	Cat# E8451
phRL-TK	Promega	Cat# E6241
pmirGLO	Promega	Cat# E1330
Software and algorithms		
GraphPad Prism 7.0	https://www.graphpad.com:443/	N/A
Ingenuity Pathway Analysis	https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/content-exploration-and-databases/qiagen-ipa/	N/A

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Frank J. Gonzalez (gonzalef@mail.nih.gov).

Materials availability

Plasmids generated in this study are available from the lead contact without restriction.

Data and code availability

RNA-seq data in this study have been deposited at GEO and publicly available as of the date of publication. Accession number is listed in the [Key resources table](#). Other raw data reported in this paper will be shared by the lead contact upon request.

This paper does not report original code.

Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals

All mouse studies were approved by the NCI Animal Care and Use Committee and performed in accordance with the Institute of Laboratory Animal Resources guidelines. Six-week-old male C57BL/6N mice were purchased from Charles River Laboratories. The

Ppara wild-type (*Ppara*^{+/+}) and hepatocyte-specific *Ppara* knockout (*Ppara*^{ΔHep}) mice used in this study were described previously (Brockner et al., 2017). Hepatocyte-specific *let-7b/c2* knockout (*let7b/c2*^{ΔHep}) were generated by mating *Alb-Cre* (Yakar et al., 1999) and *let7-b/c2 flox* (Madison et al., 2013) mouse lines. Mice were housed in a temperature (22°C) and light-controlled vivarium with free access to water and standard rodent chow food, 60% high fat diet (HFD) (S3282 from Bio-Serv) or 0.1% Wy-14,643 diet (F3254 from Bio-Serv). For gavage injection, Wy-14,643 was dissolved in 1% carboxymethyl cellulose and administered at 50 mg/kg. Mouse body composition was analyzed by MRI and Echo Medical Systems in Mouse Metabolism Core in NIDDK. All experiments were started with 7- to 8-week-old male mice.

METHOD DETAILS

Quantitative RT-PCR

Total RNA was extracted from frozen tissues using TRIzol reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. The purity and concentration of the total RNA were determined by a NanoDrop spectrophotometer (Thermo Fisher Scientific). One μg of total RNA was reverse transcribed using qScript cDNA synthesis kit (Quantabio). For *let-7* precursor measurement, the total RNA was treated with DNase I (Thermo Fisher Scientific) before reverse transcription. Primers for *let-7* miRNA precursors were designed at the stem portion of the hairpin structure as a previous study (Schmittgen et al., 2008). PerfeCTa SYBR Green Supermix (Quanta Bio) was used for SYBR green detection. For mature *let-7*, the total RNA was reverse-transcribed by Taqman miRNA assay (Thermo Fisher Scientific) and subjected to qRT-PCR as the manufacturer's instructions. *Actb* and *U6* snRNA were used as reference genes for mRNA and miRNA respectively. Polymerase reaction and the fluorescence detection were performed by QuantStudio 7 Flex real-time PCR system (Thermo Fisher Scientific).

Hematoxylin and eosin and oil red O staining

Freshly isolated liver tissues were embedded in OCT compound (Sakura Finetek), and rapidly frozen by liquid nitrogen. The samples were sliced and stained by HistoServe, Inc. Imaging was performed using a KEYENCE BZ-X710 microscope (Keyence).

For primary hepatocytes, 4% paraformaldehyde (Fujifilm wako chemicals), 60% oil red O solution (Muto pure chemicals) and hematoxylin (Muto pure chemicals) were used for fixation and staining respectively. Morphometric analyses were performed by ImageJ software (NIH).

Biochemical analyses for triglyceride, total cholesterol, and non-esterified fatty acid

Frozen liver tissues were homogenized by Precellys tissue homogenizer (Bertin Instruments) in 50 mM Tris-HCl with 5% Triton X-100 as previously described (Li et al., 2017). The lysate and serum samples were subjected to L-type Triglyceride M (Fujifilm Wako Diagnostics), Cholesterol E (Fujifilm Wako Diagnostics), and HR series NEFA-HR(2) (Fujifilm Wako Diagnostics) for measuring triglyceride (TG), total cholesterol (TC), and non-esterified fatty acid concentrations (NEFA), respectively.

Biochemical analysis for serum alanine aminotransferase

Serum samples were subjected to commercial ALT assay kit (Catachem) and monitored at 340 nm for 10 min with a microplate reader (BioAssay Systems).

Insulin, Glucose, and Pyruvate tolerance test

Intraperitoneal insulin, glucose, and pyruvate tolerance test was performed with the protocol provided from National Mouse Metabolic Phenotyping Center. One drop blood was taken via tail tip cut from 4 h-fasted mice. The blood glucose was measured by glucometer for a baseline. Then, 0.5 U/mL Humalin R (Eli Lilly), 20% Dextrose (Hospira) and sodium pyruvate (Sigma) was intraperitoneally injected to the mice at 0.5 U/kg, 1g/kg and 1g/kg, respectively. Blood glucose was measured at 15, 30, 45, 60, and 120 min after injection.

Construction of hepatocyte-specific *let-7* sponge and pre-*let-7c-1* expression adeno-associated virus (AAV) vector

The albumin promoter-driven self-complementary EGFP-AAV plasmid (pscAAV-ALBp-EGFP) described in a previous study (Kim et al., 2019) was used as a backbone vector. Single strand *let-7* sponge and the complementary oligos shown in Figure S3A were purchased from Integrated DNA Technologies. The oligos were annealed and cloned into pscAAV-ALBp-EGFP plasmid with *Not I* and *Stu I* restriction enzymes. For pre-*let-7c-1* expression AAV, the 470 bp mouse genomic sequence around pre-*let-7c-1* was amplified using custom primers (Table S3) from a MirLet7c-1 expression plasmid (Origene). The amplified fragments were cloned into pscAAV-ALBp-EGFP plasmid with *Not I*, *Stu I*, and *EcoR V* restriction enzymes. The plasmids were transfected into HEK293T cells to produce AAV8 vectors by the triple transfection method then purified using polyethylene glycol precipitation followed by cesium chloride density gradient fractionation as previously described (Park et al., 2009). AAV was transduced into primary hepatocyte at 1×10^5 infectious unit (ifu) and one mouse at 1×10^{11} ifu via tail vein injection respectively. For validation of infection efficiency, EGFP DNA isolated from the primary hepatocytes by QIAamp DNA Mini Kit (QIAGEN) and concentrated AAV solutions were amplified by qRT-PCR, and then analyzed by comparative Ct method.

Primary hepatocyte isolation and culture

Primary hepatocytes from C57BL/6N mice were isolated by a two-step perfusion method modified from a previous study (Yagai et al., 2014). Hank's balanced salt solution (HBSS) without CaCl_2 , MgCl_2 and MgSO_4 (Thermo Fisher Scientific) was used as basic solution. 25 mL HBSS with 1mM EDTA was perfused into liver via the portal vein for one mouse. Then, 25 mL HBSS containing 0.025% collagenase type I (Thermo Fisher Scientific), 0.025% collagenase type II (Thermo Fisher Scientific), 0.005% trypsin inhibitor (Thermo Fisher Scientific) and 0.075% $\text{CaCl}_2 \cdot \text{H}_2\text{O}$ (Mallinckrodt Pharmaceuticals) was perfused. The digested liver was passed through a 70- μm cell strainer. Hepatocytes were precipitated by centrifugation at 50 x g for 2 min. The dead hepatocytes were removed by Percoll (GE Healthcare) density centrifugation at 70 x g for 10 min. Hepatocytes were cultured in collagen-coated plates (Corning) with William's Medium E (Lonza) containing 400 ng/ml dexamethasone (Sigma-Aldrich), 1 x insulin-transferrin-selenium (Sigma-Aldrich), 1 x Glutamax (Thermo Fisher Scientific), 25 mM HEPES (Thermo Fisher Scientific), and 5% FBS (Gemini).

RNA-seq and pathway analysis

Total liver RNA was prepared by RNeasy plus mini kit (QIAGEN). The purity and concentration of extracted RNA were measured by 4200 TapeStation system (Agilent). Library prep followed by RNA-sequencing were performed by the National Cancer Institute Sequencing Facility. RNA-seq library was prepared by TruSeq Stranded mRNA Library Prep (Illumina). The library was analyzed by HiSeq3000/4000 system (Illumina) with paired-end 150 read length. The RNA-seq datasets generated during this study are available at Gene Expression Omnibus (Accession number: GSE165521). The comprehensive gene expression profile was subjected to Ingenuity Pathway Analysis (QIAGEN).

Ubiquitination assay for RXR α protein

pSG5-mouse *Rxra* (Leid et al., 1992) and pCMV6-mouse *Rnf8* (Origene) expression plasmids were co-transfected into Hepa-1c1c7 cells (ATCC) using Lipofectamine 3000 (Thermo Fisher Scientific). pRK5-HA-Ubiquitin-WT (Addgene) were co-transfected for poly-ubiquitin type analysis. Three days after transfection, cell lysates were harvested with RIPA buffer. For ubiquitination assays, 20 μM MG-132 (Sigma-Aldrich) was added to the medium and the cells were cultured for 4 h before harvesting. For RXR α immunoprecipitation, rabbit monoclonal RXR α antibody (Abcam) was added to 400 μL cell lysate adjusted at 1 mg/ml protein concentration. The cell lysate was incubated at 4°C for overnight. The following day, protein A agarose (Sigma-Aldrich) was added and incubated for 2 h at 4°C. Then, the RXR α -ubiquitin complexes were added to Laemmli sample buffer (Bio-Rad) with 5% 2-mercaptoethanol and heated to 95°C for 5 min. The samples were subsequently analyzed by western blot.

Western blot analysis

Liver tissue or cell samples were lysed in RIPA buffer. 10 μg protein was added to Laemmli sample buffer (Bio-Rad) with 5% 2-mercaptoethanol at 95°C for 5 min. The samples were loaded in Criterion TGX precast gel (Bio-Rad), separated by electrophoresis, then transferred using a Trans-Blot Turbo Transfer System (Bio-Rad). The protein transferred PVDF membrane was incubated with 5% skim milk containing primary antibody overnight at 4°C. Horseradish peroxidase-conjugated secondary antibodies in 5% skim milk was incubated for two h at room temperature. After the incubation, the washed membrane was exposed to SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific) for luminol reaction. Chemiluminescence was imaged and quantified using a ChemiDoc MP Imaging System (Bio-Rad). Anti-RXR α (Abcam, ab125001) and anti-PPAR α (Abcam, ab126285) antibodies were used for the protein detection.

Dual luciferase reporter assay

Let-7adf cluster EP fragments were amplified from mouse genome by the primers listed in Table S3. The insert was digested and cloned into pGL4.27 (Promega). The constructed reporter vector and phRL-TK renilla luciferase expression vector (Promega) were co-transfected into primary hepatocyte by Lipofectamine 3000 (Thermo Fisher Scientific). Three days later, the cells were lysed using the passive lysis buffer supplied in Firefly & Renilla Luciferase Single Tube Assay Kit (Biotium). Dual luciferase assay was performed as the manufacture's protocol and Veritas Microplate Luminometer (Turner BioSystems). For the mouse *Rnf8* 3' UTR reporter assay, *Rnf8* 3' UTR wild-type (WT) and mutant (Mut) fragments in Table S1 were purchased from Integrated DNA Technologies. The UTR inserts were cloned into pmirGLO vector (Promega) for *Rnf8* 3' UTR WT and Mut reporters, respectively. 20 nM *let-7c* mimic or the scramble control (Dharmacon) was transfected into HepG2 cells by Lipofectamine 3000 (Thermo Fisher Scientific). The next day, reporter vectors were transfected using the same technique. Five days later, the cells were lysed and subjected to dual luciferase assay as same manner above.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis and graphing of the data were performed using GraphPad Prism. Data are presented as mean \pm SE for biological replicates. Statistical significance is indicated by the following annotations: * $p < 0.05$, # $p < 0.01$, § $p < 0.001$ in Figures 1A and 1C and * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ in other Figures. p values were calculated by two-sided paired t tests followed by Bonferroni analysis. Please note that statistical details are found in the figure legends.


Cell Reports, Volume 36

Supplemental information

Feedback repression of PPAR α signaling

by *Let-7* microRNA

Tomoki Yagai, Tingting Yan, Yuhong Luo, Shogo Takahashi, Daisuke Aibara, Donghwan Kim, Chad N. Brocker, Moshe Levi, Hozumi Motohashi, and Frank J. Gonzalez



Supplemental Figure 1. Lin28 expressions in liver and phenotypic analyses of *let7b/c2*^{+/+} and *let7b/c2*^{ΔHep} mice. Related to Figure 1 and 2.


(A and B) Fold change of Lin28a (A) and Lin28b (B) mRNA abundance in Wy-14,643 treated liver. N.D.: Non-Detected.

(C and D) Fold change of *pre-let-7b* and *pre-let-7c-2* (C) and mature *let-7b* and *let-7c* (D) abundance in *let7b/c2*^{+/+} and *let7b/c2*^{ΔHep} livers.

(E) Average daily food intake (kcal/mouse/day) of *let7b/c2*^{+/+} and *let7b/c2*^{ΔHep} when HFD-feeding.

(F-J) Biochemical analyses for serum total cholesterol (TC) (F); alanine aminotransferase activity (ALT) (G); hepatic triglycerides (TG) (H); hepatic TC (I); and hepatic non-esterified fatty acid (NEFA) (J) in *let7b/c2*^{+/+} and *let7b/c2*^{ΔHep} mice after HFD-feeding.

(K) Heat map of FXR target genes identified by differential gene expression analysis of RNA-seq data from *let7b/c2*^{+/+} and *let7b/c2*^{ΔHep} livers after HFD-feeding. n = 5 mice/ group. Data are presented as mean ± SEM.













Supplemental Figure 2. Biochemical assays for normal chow diet-fed *let7b/c2^{+/+}* and *let7b/c2^{ΔHep}* mice. Related to Figure 2.

Body weight alterations of *let7b/c2^{+/+}* and *let7b/c2^{ΔHep}* mice during normal chow diet-feeding. Average daily food intake (kcal/mouse/day). N = 5 mice/ group. Data are presented as mean \pm SEM.

(B-E) Biochemical analyses for serum TG (B); serum TC (C); Hepatic TG (D); and Hepatic TC (E) in *let7b/c2^{+/+}* and *let7b/c2^{ΔHep}* mice after normal chow diet-feeding.

(F-H) ITT (F); GTT (G); and PTT (H) for normal chow diet-fed *let7b/c2^{+/+}* and *let7b/c2^{ΔHep}* mice.

(I) mRNA analysis by qRT-PCR of PPAR α target genes in *let7b/c2^{+/+}* and *let7b/c2^{ΔHep}* livers after 1-week HFD-feeding. n = 5 mice/ group. Data are presented as mean \pm SEM.



Supplemental Figure 3. let-7 sponge AAV construction and phenotypes of let-7 sponge AAV-transduced mice related to Figure 2.

(A) Sequence of let-7 sponge inserted in let-7 sponge AAV vector.

(B) Scheme of let-7 sponge expression AAV vector.







(C) qPCR analysis of GFP DNA in primary hepatocytes transduced by EGFP and let-7 sponge expressing AAV.

(D) Oil Red O staining of liver sections from wild-type mice infected with EGFP or let-7 sponge expressing AAV after being on HFD for eight weeks. Bars = 100 μ m







(E-H) Biochemical analyses for serum TC (D); hepatic TG (E); hepatic TC (F); and hepatic NEFA (G) concentration in EGFP and let-7 sponge AAV-infected mice after HFD-feeding.

(I and J) ITT (H); and GTT (I) for normal chow diet-fed EGFP and let-7 sponge AAV-infected mice.

Data are presented as mean \pm SEM. (n = 4-5 mice per group; *p < 0.05)



I *RXRα* - + +
RNF8 - - +



Supplemental Figure 4. RXR α expressions, functions and protein ubiquitination by let-7 miRNA related to Figure 3 and 4.

- (A-B) Fold change of PPAR α (A); and RXR α (B) mRNA in *let7b/c2^{+/+}* and *let7b/c2 Δ ^{Hep}* livers fed HFD.
- (C) Fold change of RXR α mRNA in *let7b/c2^{+/+}* and *let7b/c2 Δ ^{Hep}* primary hepatocytes.
- (D) Fold change of RXR α mRNA in EGFP, pre-let-7c-1 and let-7 sponge AAV-transduced liver after HFD-feeding.
- (E) Oil red O staining and the morphometric analysis for lipid accumulation in mouse primary hepatocytes treated with Palmitic acid (800 μ M) and/or HX-531 (5 μ M).
- (F) Western blot analysis and the densitometric quantification of RXR α in 60% HFD and/or Wy-14,643-treated mouse livers.
- (G) Fold change of *Rnf8* mRNA in EGFP and pre-let-7c-1 AAV-transduced liver.
- (H) Western blot analysis and the densitometric quantification of RXR α in *Rxra* transfected Hepa-1 cells treated with the proteasome inhibitor MG-132.
- (I) Western blot analysis of K48 polyubiquitin chain in *Rxra* and *Rnf8* transfected Hepa-1 cells.
- (J) Western blot analysis of RNF8 protein in *Rnf8* transfected Hepa-1 cells.
- Data are presented as mean \pm SEM. (n = 4-5 blots or fields per group; *p < 0.05, **p < 0.01, ***p < 0.001)

Supplemental Table 1. *let-7* microRNA family in mice related to Figure 1

Mature <i>let-7</i> microRNA	Precursor	Primary transcript	Clustered <i>let-7</i> precursor	Chromosome	miRBase ID
<i>let-7a</i>	<i>pre-let-7a-1</i>	let-7adf cluster	<i>pre-let-7d, pre-let-7f-1</i>	Chr.13	MI0000556
	<i>pre-let-7a-2</i>	3110039I08Rik		Chr.9	MI0000557
<i>let-7b</i>	<i>pre-let-7b</i>	Lincppara	<i>pre-let-7c-1</i>	Chr.15	MI0000558
<i>let-7c</i>	<i>pre-let-7c-1</i>	2810055G20Rik	<i>pre-let-7b</i>	Chr.16	MI0000559
	<i>pre-let-7c-2</i>	Lincppara		Chr.15	MI0000560
<i>let-7d</i>	<i>pre-let-7d</i>	let-7adf cluster	<i>pre-let-7a-1, pre-let-7f-1</i>	Chr.13	MI0000405
<i>let-7e</i>	<i>pre-let-7e</i>	Spaca6		Chr.17	MI0000561
<i>let-7f</i>	<i>pre-let-7f-1</i>	let-7adf cluster	<i>pre-let-7a-1, pre-let-7d</i> <i>pre-miR-98</i>	Chr.13	MI0000562
	<i>pre-let-7f-2</i>	Huwe1		Chr.X	MI0000563
<i>let-7g</i>	<i>pre-let-7g</i>	Wdr82		Chr.9	MI0000137
<i>let-7i</i>	<i>pre-let-7i</i>	mmu-let-7i		Chr.10	MI0000138
<i>miR-98</i>	<i>pre-miR-98</i>	Huwe1	<i>pre-let-7f-2</i>	Chr.X	MI0000586

Summary of mature *let-7* miRNA, the precursors and the primary transcripts. Mature *let-7a*, *c* and *f* are processed from two precursors. *Pre-let-7a-1*, *pre-let-7d* and *pre-let-7f-1* are processed from an identical primary transcript. *Pre-let-7b* and *pre-let-7c-1* are also processed from an identical primary transcript

Supplemental Table 2. Downregulated pathways in *let7b/c2*^{ΔHep} mouse liver compared with *let7b/c2*^{+/+} related to Figure 3

Upstream Regulator	Expr Log Ratio	Molecule Type	Predicted Activation State	Activation z-score
PPARA	0.032	ligand-dependent nuclear receptor	Inhibited	-6.751
INSIG1	0.13	other	Inhibited	-3.564
Alpha catenin		group	Inhibited	-3.389
HOXA3		transcription regulator	Inhibited	-3.357
CFTR		ion channel	Inhibited	-3.194
PPARG	-1.333	ligand-dependent nuclear receptor	Inhibited	-3.171
NR1H4	0.035	ligand-dependent nuclear receptor	Inhibited	-3.134
PPARD	0.348	ligand-dependent nuclear receptor	Inhibited	-3.119
KLF15	0.058	transcription regulator	Inhibited	-2.721
LPL	1.748	enzyme	Inhibited	-2.619
TP73		transcription regulator	Inhibited	-2.601
PNPLA2	0.618	enzyme	Inhibited	-2.498
LCAT	-0.135	enzyme	Inhibited	-2.449
ABCG1	0.414	transporter	Inhibited	-2.433
INSIG2	-0.922	other	Inhibited	-2.415
let-7a-5p (and other miRNAs w/seed GAGGUAG)		mature microRNA	Inhibited	-2.414
ZFP36	-0.182	transcription regulator	Inhibited	-2.412
let-7		microRNA	Inhibited	-2.401
ZBTB20	0.568	transcription regulator	Inhibited	-2.4

Pathway analysis for RNA-seq data from 60% HFD-fed *let7b/c2*^{+/+} and *let7b/c2*^{ΔHep} mouse livers. PPAR and FXR pathways (blue labeled) were significantly repressed by *let7b/c2* deletion in liver.

Supplemental Table 3. Primers and Oligos used in this paper related to STAR Methods

Primers for mouse Quantitative RT-PCR		
	Forward (5' to 3')	Reverse (5' to 3')
<i>pre-Let-7a-1</i>	TTAGGGTCACACCCACCAC	ATCACCTTAGGAAAGACAGTAGATTG
<i>pre-Let-7a-2</i>	TAGAGTTACATCAAGGGAGATAACTG	GTGCAAGTCCCAAGGAAAG
<i>pre-Let-7b</i>	TCAGGGCAGTGATGTTGCC	TCAGGGAAGGCAGTAGGTTG
<i>pre-Let-7c-1</i>	GAGTTACACCCTGGGAGTTAACTG	AGTGTGCTCCAAGGAAAGCTAG
<i>pre-Let-7c-2</i>	TTTTGGGCTCTGCCCCGC	GCGGCCACTTCAGGAAAGACAG
<i>pre-Let-7d</i>	TTAGGGCAGAGATTTTGCCC	GCCCTAAGAAAGGCAGCAGG
<i>pre-Let-7e</i>	TGAGGAAGACACCCGAGGAG	GCAGCCTGGGGAAAGCTAG
<i>pre-Let-7f-1</i>	GTGGGGTAGTGATTTTACCCTG	CTCAGGGAAGGCAATAGATTGTATAG
<i>pre-Let-7f-2</i>	TTAGGGTCATACCCCATCTTGG	CGTGGGAAAGACAGTAGACTGTATAG
<i>pre-Let-7g</i>	TGAGGGTCTATGATACCACCCG	GCAAGGCAGTGGCCTGTAC
<i>pre-Let-7i</i>	GGTCGGGTTGTGACATTGC	CTAGCAAGGCAGTAGCTTGCG
<i>pre-miR98</i>	GTGGGGTAGGGATTTTAGGCC	ATGCCACACACCAAGGAAAGTAG
<i>Cyp4a14</i>	CCTGACTTTCTTTCGCCTGC	TGATCACTCCATCTGTGTGCT
<i>Ehhadh</i>	CCGGTCAATGCCATCAGT	CCGGTCAATGCCATCAGT
<i>Hadha</i>	AGGATCCTACGCTCCAGAGG	AAGCAGGATCCACTGATGGC
<i>Krt23</i>	CTGATTCAGCTCCGCCAAGA	TCCATCGTCCCTTCAGTGTC
<i>Aldh3a2</i>	GGTCAAACCTGCATTGCTCC	TCCCATAAAAAGTCCTCACCG
<i>Cidea</i>	GACAGAAATGGACACCGGGTA	TGACATTGAGACAGCCGAGG
<i>Cidec</i>	TGGCACAATCGTGGAGACAG	CTCTCTTCTTGCCTGTTCTG
<i>Gpam</i>	TGTGTACCCGAAGGTCTCCA	TGTTTACATCGGCCAAGGCT
<i>Pctp</i>	GGCTCTCCTCGCAGATGTTT	TGAGCCAGGACGGAATTTGG
<i>Gyk</i>	TGGCCTAATGAAAGCTGGGG	TGCACTGGGCTCCCAATAAG
<i>Gapdh</i>	AGGTCGGTGTGAACGGATTTG	TGTAGACCATGTAGTTGAGGTCA
<i>Ppara</i>	CACGCATGTGAAGGCTGTAA	CACGCATGTGAAGGCTGTAA
<i>Rxra</i>	CTCAATGGCGTCCCAAGGT	ACCCCATAGTGTGGCCTGAG
<i>Rnf8</i>	GACTTTCCAGGAGGAGGCAC	CCAGGGAGTTGGTTCTGGAC
<i>Egfp</i>	AAGCTGACCCTGAAGTTCATCTGC	CTTGTAGTTGCCGTCGTCCTTGAA
Oligos for Let-7 sponge AAV construction (5' to 3')		
Let-7 sponge	GGCCGCAACCATAACAAGGACTACCTCAATGCATGCAACCATAACATGGACTACCTCAATGCATGCAACCATAACAAGG ACTACCTCAATGCATGCAACCATAACATGGACTACCTCAATGCATGCAACCATAACAAGGACTACCTCAATGCATGCAA CCATACATGGACTACCTCAGGATCCT	
Let-7 sponge complement	CTAGAGGATCCTGAGGTAGTCCATGTATGGTTGCATGCATTGAGGTAGTCCCTTGTATGGTTGCATGCATTGAGGTAG TCCATGTATGGTTGCATGCATTGAGGTAGTCCCTTGTATGGTTGCATGCATTGAGGTAGTCCATGTATGGTTGCATGC ATTGAGGTAGTCCCTTGTATGGTTGC	
Primers for <i>pre-Let-7c-1</i> AAV construction (5' to 3')		
Let-7c-1 NotI EcoRV	AAAGCGCCGCTAATGGAAGTGTGGTCAAGG	AAAGATATCGCGTTGTGTCATTGCTTACAAG
Oligos for <i>Rnf8</i> 3'UTR luciferase reporter vectors		
<i>Rnf8</i> 3'UTR Wild-type	AAAGCTAGCGACTGAGTTAGGAAGTCTGTGCCACTGGCCTCCGTCATGCAGGCCCTGCTGCTACCACCCCCCAA CGTGTGCTGGGACCCTGCTCGGACTGCCTGACTGTGCATTAATGAGTTGAGTTCTGTGTTTCTTAATTTGTTGATT GTTTTTGATACCTCATGCACCCTCTTGACATCATTGTGGACAGCTGGGTGTGAGTCCTGTGGCTGTGTGGAAGGT GGCCTGCATTTTGAGAGCCTGGTTTACCTTTTATGAAAACATGATGTCATTTCTTGGGAATAAAATGTATAAACTC TCAGTTGCTCAGCTGGCTCGAGAAA	
<i>Rnf8</i> 3'UTR Mutant	AAAGCTAGCGACTGAGTTAGGAAGTCTGTGCCACTGGCCTCCGTCATGCAGGCCCTGCTGCTACCACCCCCCAA CGTGTGCTGGGACCCTGCTCGGACTGCCTGACTGTGCATTAATGAGTTGAGTTCTGTGTTTCTTAATTTGTTGATT GTTTTTGAGCGGCCGCTGCACCCTCTTGACATCATTGTGGACAGCTGGGTGTGAGTCCTGTGGCTGTGTGGAAG GTGGCCTGCATTTTGAGAGCCTGGTTTACCTTTTATGAAAACATGATGTCATTTCTTGGGAATAAAATGTATAAAAC TCTCAGTTGCTCAGCTGGCTCGAGAAA	

Primers and oligos used for qRT-PCR. AAV constructs and *Rnf8* 3'UTR reporter vectors.